Please login to the form below

Not currently logged in
Email:
Password:

drisapersen

This page shows the latest drisapersen news and features for those working in and with pharma, biotech and healthcare.

CHMP backs two rare disease therapies at April meeting

CHMP backs two rare disease therapies at April meeting

The importance of Brineura to the company has gained prominence after it was forced to ditch Duchenne muscular dystrophy drug drisapersen in the face of regulatory resistance to approval.

Latest news

More from news
Approximately 6 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Licence. 935. Prosensa / BioMarin. Drisapersen – for Duchenne muscular dystrophy.

  • Pharma deals during November 2014 Pharma deals during November 2014

    additional $160m more in near-term milestones if drisapersen, the late-stage drug for Duchenne muscular dystrophy (DMD), secures “early” approval. ... $20.31 before settling at around $19.00.  Prosensa has been busy since drisapersen failed a

  • Pharma deals during January 2014 Pharma deals during January 2014

    Terminations. Not surprisingly after the report of the failure of drisapersen in showing improvement in its phase III six minute walking study in Duchenne muscular dystophy, GSK announced the return of ... the drisapersen rights to Prosensa.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics